Therefore, the combined inhibition of miR-21 and the blocking of IL-6 receptor may be a potential treatment for reversing cisplatin resistance in ESCC through the downregulation of STAT3 signaling [133]. This evidence concerns the gene STAT3 and esophageal squamous cell carcinoma.